Strides Pharma Science Share price

Q: How to buy Strides Pharma Science Share at Choice?

To buy Strides Pharma Science stocks , log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Strides Pharma Science, choose your preferred order type, and place the trade.

STAR

Healthcare Large Cap

1153.2

5.90 (-0.51%)

NSE

BSE

Last updated on 22 May, 2026 | 15:40 IST

BUYSELL

Today's High

1169.70

Today's Low

1137.90

52 Week Low

660.05

52 Week High

1231.00

Free Demat with Zero AMC*

Strides Pharma Science Chart

ChartIQ

TradingView

Strides Pharma Science Share Key Metrics

Volume

1.50 L

Market Cap

10629.36 CR

LTQ@LTP

9@1153.20

ATP

1155.42

Var Margin

20.41 %

Circuit Range

927.3-1390.9

Delivery %

36.2 %

Value

17.36 CR

ASM/GSM

No

Market Lot

1

Summary

Strides Pharma Science share price is ₹1153.2 as of 22 May, 2026. The stock Strides Pharma Science intraday movement has stayed between ₹1137.90 and ₹1169.70, while on a 52-week basis,Strides Pharma Science price 52 week high is ₹1231.00 & its 52 week low is ₹660.05.

In terms of trading activity, Strides Pharma Science has recorded a volume of 150266 shares, The Strides Pharma Science has a market cap of ₹92172714 CR. The stock’s Average Traded Price (ATP) stands at ₹1155.42, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 9 @ ₹1153.20.

Strides Pharma Science operates within a circuit range of ₹927.30 – ₹1390.90, with a Value of ₹17.36 CR. The Delivery Percentage for the day is 36.2%. Additionally, Strides Pharma Science currently falls under the No framework, and trades with a market lot size of 1.

Strides Pharma Science Fundamentals

P/E Ratio

19.21

P/B Ratio

3.44

Div. Yield

0.43

Sector P/E

71.49

Sector P/B

3.47

Sec. Div. Yield

0.55

Strides Pharma Science Resistance and Support

Pivot 1154.5

Resistance

First Resistance

1177.9

Second Resistance

1196.7

Third Resistance

1220.1

Support

First Support

1135.7

Second Support

1112.3

Third Support

1093.5

Strides Pharma Science Shareholding Pattern

2021-22
2024-25
2025-26
2026-27
2023-24
2022-23
2020-21
2019-20
2018-19

Total Promoters

Segment

Percent

Total Promoters

30.89%

Mutual Fund

11.65%

Insurance

5.26%

Foreign Institutional Investors

18.93%

Domestic Institutional Investors

1.99%

Retail

31.28%

Others

0%

Total Promoters

MAR '22

30.6%

JUN '22

30.37%

SEP '22

31.07%

DEC '22

30.89%

Strides Pharma Science Corporate Actions

Date	Agenda
2026-05-18	Audited Results & Final Dividend
2026-01-30	Quarterly Results
2025-10-31	Quarterly Results
2025-07-29	Quarterly Results
2025-05-22	Audited Results & Final Dividend
2025-01-30	Quarterly Results

Strides Pharma Science News

Strides Pharma Science Limited

Strides Pharma received a USFDA Form 483 with five observations after a cGMP inspection at its Bangalore facility. The company will respond to the observations within the stipulated time, with potential implications for compliance and operations.

May 20 2026 22:05:00

Strides Pharma Science Ltd - 532531 - Completion Of US-FDA Inspection At The Company'S Flagship Facility In Bangalore

Strides Pharma Science's flagship manufacturing facility in Bangalore underwent a US-FDA inspection, resulting in a Form 483 with five observations. The company will address these observations promptly to the FDA.

May 20 2026 22:05:00

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Change in Directorate

Strides Pharma Science has elevated Mr. Venkata Seetharama Raju Pakalapati from COO to Executive Director for a 3-year term, effective June 1, 2026. Concurrently, Mr. Aditya Arun Kumar has been redesignated from Executive Director to Non-Executive Director.

May 20 2026 15:05:00

Strides Pharma Science Limited

Strides Pharma appointed Venkata Seetharama Raju Pakalapati as Executive Director and Key Managerial Personnel (KMP), effective June 1, 2026. He will oversee global technical operations and strategic management.

May 20 2026 15:05:00

Strides Pharma Science Limited

Strides Pharma announced leadership changes, with Venkata Seetharama Raju Pakalapati elevated to Executive Director and KMP, effective June 1, 2026. Concurrently, Aditya Arun Kumar transitioned from Executive to Non-Executive Director, ceasing to be a KMP from May 31, 2026, as part of management professionalization.

May 20 2026 15:05:00

Strides Pharma Science Ltd - 532531 - Pronouncement Of Order By The Hon'Ble NCLT, Bengaluru Bench Regarding Scheme Of Arrangement For Demerger Of Demerged Undertaking Of Arco Lab Private Limited, A Wholly Owned Subsidiary Of Strides Pharma Science Limited.

Strides Pharma Science received NCLT approval for the scheme of arrangement to demerge Arco Lab's Life Sciences and Digital Innovation businesses into Pivot Path, effective April 10, 2025. This move aims to streamline its corporate structure.

May 20 2026 13:05:00

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Strides Pharma Science has published the audio recording of its earnings call, held today, May 18, 2026. This recording covers discussions on the audited financial results for Q4 and the full financial year ended March 31, 2026, and is accessible on the company's website.

May 18 2026 19:05:00

Strides Pharma Science Limited

Strides Pharma appointed Mr. Venkata Seetharama Raju Pakalapati as Executive Director for three years, effective June 1, 2026. Concurrently, Mr. Aditya Arun Kumar was redesignated as Non-Executive Director from his executive role.

May 18 2026 18:05:00

Strides Pharma Science Limited

Strides Pharma Science Limited's board has recommended a final dividend of Rs. 5 per equity share, representing 50% for the financial year ended March 31, 2026. The record date for the dividend will be announced later.

May 18 2026 18:05:00

Strides Pharma Science Limited

Strides Pharma Science's Board approved significant leadership changes, including the elevation of Venkata Seetharama Raju Pakalapati to Executive Director and KMP, effective June 1, 2026. Aditya Arun Kumar was redesignated to Non-Executive Director.

May 18 2026 16:05:00

NSE : 7374

BSE : 532531

ISIN : INE939A01011

Strides Pharma Science Management

Name	Position
Arun Kumar	Chairman
Kausalya Santhanam	Non Executive Independent Director

Strides Pharma Science Similar Stocks

Sanofi Consumer Healthcare India Ltd.

4735.10

46.20 (0.99%)

Park Medi World Ltd.

259.19

3.43 (1.34%)

Viyash Scientific Ltd.

246.06

-1.48 (0.60%)

Metropolis Healthcare Ltd.

518.95

-9.85 (1.86%)

CORONA Remedies Ltd.

1684.60

-21.80 (1.28%)

Marksans Pharma Ltd.

211.86

-4.31 (1.99%)

Healthcare Global Enterprises Ltd.

654.30

27.30 (4.35%)

Shilpa Medicare Ltd.

490.25

15.60 (3.29%)

Procter & Gamble Health Ltd.

5553.00

98.00 (1.80%)

Jupiter Life Line Hospitals Ltd.

1356.60

44.60 (3.40%)

Strides Pharma Science FAQs

The Buying Price of Strides Pharma Science share is 1153.2 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Strides Pharma Science stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Strides Pharma Science, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Strides Pharma Science shares is 19.21. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Strides Pharma Science shares is 3.44. Useful to assess the stock's value relative to its book value.

To assess Strides Pharma Science’s valuation compare Sector P/E, P/B which are 71.49 & 3.47 with sector averages, along with growth rates and financial metrics.

The Market Cap of Strides Pharma Science is 10629.36 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Strides Pharma Science share price is 1231.00 & 660.05. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Strides Pharma Science belongs to the Healthcare sector.